GW Pharmaceuticals Plc
GW PHARMACEUTICALS PLC (Form: 6-K, Received: 09/11/2017 16:03:09)

 

 

United States

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

  

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Month of September, 2017

 

Commission File Number: 001-35892

 

GW PHARMACEUTICALS PLC

(Translation of registrant’s name into English)

  

Sovereign House

Vision Park

Histon

Cambridge CB24 9BZ

United Kingdom

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F   x   Form 40-F   ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

 

Yes   ¨   No   ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

 

Yes   ¨   No   ¨

 

 

 

 

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

On September 11, 2017, GW Pharmaceuticals plc (the “Company”) issued a notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them (the “Notification”). The Notification is attached as Exhibit 99.1 hereto and is incorporated by reference herein. The information in the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Exhibits

 

99.1       Notification dated September 11, 2017

 

 

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  GW Pharmaceuticals plc
     
  By: /s/ Adam George
  Name:   Adam George
  Title:   Company Secretary
     
Date: September 11, 2017    

 

 

Exhibit 99.1

 

Notification and public disclosure of transactions by persons discharging

 

managerial responsibilities and persons closely associated with them

 

1.          Details of the person discharging managerial responsibilities / person closely associated
a.          Name Mr Julian Gangolli
2.          Reason for the notification
a.          Position/status Director/President, US
b.         

Initial notification

 

/Amendment

 

Initial notification
3.          Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.          Name GW Pharmaceuticals PLC
b.          LEI  
4.          Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.         

Description of the

 

Financial instrument, type of instrument

 

Identification code

 

 

 

Ordinary shares of 0.1p each

 

ISIN: GB0030544687

 

b.          Nature of the transaction

Exercise of share options to acquire ordinary shares.

 

 

 

c.          Price(s) and volume(s)

 

  Price(s)            Volume(s)  

  

  0.1p                  38,016                Ordinary shares acquired pursuant to option exercise

d.         

Aggregated information

 

Aggregated volume

 

Price

 

 

 

 

 

n/a

 

e.          Date of the transaction 8 September 2017
f.          Place of the transaction

London

 

 

 

 

 

 

 

4.          Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.         

Description of the

 

Financial instrument, type of instrument

 

Identification code

 

Ordinary shares of 0.1p each and American Depositary Shares

 

 Ordinary Shares: ISIN: GB0030544687

 

American Depositary shares: ISIN: US36197T1034

 

b.          Nature of the transaction Conversion of Ordinary shares into American Depositary Shares (12 to 1 conversion ratio)
c.          Price(s) and volume(s)

 

  Price(s)             Volume(s)

 

   -                        1,510                     ADS’s issued upon conversion of 18,120 Ordinary shares

d.         

Aggregated information

 

Aggregated volume

 

Price

 

  

 

n/a

 

e.          Date of the transaction 11 September 2017
f.          Place of the transaction New York
4.          Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.         

Description of the

 

Financial instrument, type of instrument

 

Identification code

 

 

 

 

 

American Depositary Shares

 

ISIN: 36197T1034

 

b.          Nature of the transaction Sale of American Depositary shares
c.          Price(s) and volume(s)

 

  Price(s)            Volume(s) 

 

  $108.43             1,510                    ADS’s sold to cover taxes due on option exercise

d.         

Aggregated information

 

Aggregated volume

 

Price

 

 

 

 

 

n/a

 

 

 

 

 

e.          Date of the transaction 11 September 2017
f.          Place of the transaction Nasdaq, New York
4.          Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.         

Description of the

 

Financial instrument, type of instrument

 

Identification code

 

Ordinary Share and Restricted American Depositary Shares

 

Ordinary Shares: ISIN: GB0030544687

 

Restricted American Depositary shares: ISIN: US36197T1372

 

b.          Nature of the transaction Conversion of 19,896 Ordinary Shares arising from option exercise into 1,658 Restricted American Depositary shares  (12 to 1 Conversion ratio), increasing Julian Gangolli’s closing shareholding to 2,241 Restricted ADSs.
c.          Price(s) and volume(s)

 

  Price(s)          Volume(s)

 

  -                      1,658                   Restricted ADSs issued upon conversion of 19,896

                                                     Ordinary Shares being retained

d.         

Aggregated information

 

Aggregated volume

 

Price

 

 

 

n/a

 

e.          Date of the transaction 11 September 2017
f.          Place of the transaction Nasdaq, New York